Exposure to autoimmune disorders increases Alzheimer's disease risk in a multi-1

- 2 site electronic health record analysis
- 3 Grace D. Ramey^{1,2}, Alice Tang^{2,3}, Thanaphong Phongpreecha^{4,5,6}, Monica M. Yang⁷, Sarah R.
- Woldemariam², Tomiko T. Oskotsky^{2,8}, Thomas J. Montine⁴, Isabel Allen⁹, Zachary A. Miller¹⁰, 4
- Nima Aghaeepour^{5,6,11}, John A. Capra^{2,9,*}, Marina Sirota^{2,8,9,*} 5
- 6
- 7 1 Biological and Medical Informatics PhD Program, UCSF, San Francisco, CA
- 8 2 Bakar Computational Health Sciences Institute, UCSF, San Francisco, CA
- 9 3 School of Medicine, UCSF, San Francisco, CA
- 10 4 Department of Pathology, Stanford University, Palo Alto, CA
- 5 Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University, Palo 11 12 Alto, CA
- 13 6 Department of Biomedical Data Science, Stanford University, Palo Alto, CA
- 14 7 Department of Medicine, Division of Rheumatology, UCSF, San Francisco, CA
- 15 8 Department of Pediatrics, UCSF, San Francisco, CA
- 9 Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA 16
- 17 10 Memory and Aging Center, UCSF, San Francisco, CA
- 18 11 Department of Pediatrics, Stanford University, Palo Alto, CA
- 19
- 20 *Corresponding authors information:
- 21 John A. Capra
- 22 UCSF Bakar Computational Health Sciences Institute. San Francisco. CA 94143
- 23 tony@capralab.org
- 24
- 25 Marina Sirota
- 26 UCSF Bakar Computational Health Sciences Institute, San Francisco, CA 94143
- 27 Marina.Sirota@ucsf.edu
- 28
- 29 Conflict of interest: The author has declared that no conflict of interest exists.

30 Abstract

31 Molecular studies of Alzheimer's disease (AD) implicate potential links between autoimmunity 32 and AD, but the underlying clinical relationships between these conditions remain poorly 33 understood. Electronic health records (EHRs) provide an opportunity to determine the clinical 34 risk relationship between autoimmune disorders and AD and understand whether specific 35 disorders and disorder subtypes affect AD risk at the phenotypic level in human populations. We 36 evaluated relationships between 26 autoimmune disorders and AD across retrospective 37 observational case-control and cohort study designs in the EHR systems at UCSF and Stanford. 38 We quantified overall and sex-specific AD risk effects that these autoimmune disorders confer. 39 We identified significantly increased AD risk in autoimmune disorder patients in both study 40 designs at UCSF and at Stanford. This pattern was driven by specific autoimmunity subtypes including endocrine, gastrointestinal, dermatologic, and musculoskeletal disorders. We also 41 42 observed increased AD risk from autoimmunity in both women and men, but women with 43 autoimmune disorders continued to have a higher AD prevalence than men, indicating 44 persistent sex-specificity. This study identifies autoimmune disorders as strong risk factors for 45 AD that validate across several study designs and EHR databases. It sets the foundation for 46 exploring how underlying autoimmune mechanisms increase AD risk and contribute to AD 47 pathogenesis.

48

49 Introduction

Alzheimer's disease (AD) is a debilitating neurodegenerative disease that is accompanied by enormous social and economic burdens, and its prevalence is increasing due to the growing aging population worldwide (1,2). AD is characterized biologically by amyloid plaques and tau deposition in the brain, while clinical syndromic diagnoses, such as specific forms of progressive memory loss, have evolved with the development of better AD diagnostic tests and biomarkers

55 (3,4). Treatments that slow cognitive decline have been a large focus of AD research over the 56 past several years (5), and understanding of underlying risks and pathogenesis in order to treat 57 the disease at an earlier stage is especially important considering that current treatments are 58 still unable to fully rescue normal cognition (6).

59 Many prior molecular and genetic studies suggest a potential role of the immune system and 60 chronic inflammation in AD pathogenesis (7-9). Indeed, over half of the genetic variants associated 61 with AD to date are primarily expressed in immune cells (10). Furthermore, several studies point to 62 immune pathways like the NLRP3 inflammasome (11) and complement system (12-14) becoming 63 dysregulated in AD experimental animal and human models. However, the extent of contribution of 64 immune system dysfunction to AD remains poorly understood at the clinical phenotype level in 65 diverse human populations. Autoimmune disorders are one potential source of chronic immune dysregulation, and their clinical risk relationship with neurodegenerative diseases like AD has vet to 66 67 be fully characterized. Furthermore, autoimmune disorders exhibit a similar sex disparity to AD 68 (15,16), affecting women more so than men (17-19), suggesting a potential relationship between 69 biological mechanisms and clinical manifestations that has yet to be quantified. Therefore, studying 70 risk relationships in individuals with autoimmune disorders and AD will provide a powerful way 71 to understand the role of autoimmunity as a risk factor for AD overall and across sexes. 72 With advances in curation of real-world datasets (20), such as electronic health records 73 (EHRs), there is a great opportunity to investigate clinical risk relationships between many 74 autoimmune disorders and AD. The large sample sizes that EHRs provide also allow for robust 75 analyses that can be stratified in a sex- and disease-specific manner and validated across 76 hospital sites. Here, we examine risk associations between AD and 26 different autoimmune 77 disorders in the UCSF EHR system, and we further stratify our analyses by sex to holistically 78 understand the biological effects of immune dysfunction on AD pathogenesis at the phenotypic 79 level. We show that there is a clear and strong risk association between autoimmune disorders 80 and AD overall and in both men and women, but that women with autoimmune disorders

continue to have the highest AD prevalence compared to men with autoimmune disorders. We
show evidence for increased AD risk effects from particular autoimmune disorders and disorder
subtypes, and we further investigate the timing of AD onset in autoimmune disorders patients.
Finally, we provide robust validation of our risk associations from the Stanford EHR system to
demonstrate stability of risk signals across different study designs and mitigate potential
confounding factors.

87

88 Results

89 We selected patients with autoimmune disorders and/or AD for case-control and cohort study 90 designs from the UCSF and Stanford EHR databases, which contain information on over 5 91 million and 3.8 million patients, respectively. For patients with autoimmune disorders, we 92 identified individuals with each of 26 different autoimmune disorders of interest (Table S1), and 93 type 1 diabetes, rheumatoid arthritis, autoimmune thyroiditis, and inflammatory bowel disease 94 were among the most prevalent in the study groups. The case-control study groups consisted of 95 7,812 individuals (3,906 AD patients and 3,906 non-AD controls, Fig 1, S1) from UCSF and 96 13,292 individuals (6,646 AD patients and 6,646 non-AD controls, Fig 1, S1) from Stanford. The 97 cohort study groups consisted of 27,630 individuals (13,815 autoimmune disorder patients and 98 13.815 non-autoimmune controls, Fig 1, S1) from UCSF and 260,516 individuals (130,258 99 autoimmune disorder patients and 130,258 non-autoimmune controls, Fig 1, S1) from Stanford. 100 In the UCSF data set, the mean $(\pm SD)$ lifespan in the case-control group was 80.05 (± 6.74) 101 years for AD patients and 80.07 (±6.73) years in non-AD controls, while in the cohort study 102 group, the mean lifespan for autoimmunity patients was 69.25 (±13.21) years and 69.10 103 (±13.38) years for non-autoimmune controls. Because individuals had a higher proportion of 104 censored death information in the Stanford data set, these people were assessed by birth year 105 rather than lifespan, and we verified that this difference would not significantly influence results

106 (see Methods and Sensitivity Analyses). In the Stanford data set, the mean birth year (±SD) was 107 1934.53 (±10.11) for AD patients and 1934.50 (±10.07) for non-AD controls in the case-control 108 study group, while in the cohort study group, the mean birth year both for autoimmunity patients 109 and non-autoimmune controls was 1968.38 (±21.83) (Table 1). Women made up a majority of 110 each of our study groups, representing 61.9% (case-control) and 57.9% (cohort) of individuals in 111 the UCSF study groups, and 62.3% (case-control) and 64.9% (cohort) of individuals in the 112 Stanford study groups. Further demographic information across study designs and EHR data 113 sets is listed in Table 1. 114 We compared the risk of being diagnosed with AD in patients with autoimmune disorders

115 compared to non-autoimmune controls across case-control and cohort study designs in both the 116 discovery (UCSF) and validation (Stanford) data sets. We evaluated the risk of AD in the study 117 groups both overall and in a sex-stratified manner across multiple levels of autoimmune disorder 118 stratifications to determine specific autoimmune drivers of AD risk.

119

120 Autoimmune disorder diagnoses are significantly associated with increased risk of AD

121 overall and within sex-specific groups

- 122 In the case-control study groups, overall, individuals with autoimmune disorders had
- significantly higher odds of an AD diagnosis compared to non-autoimmune controls in both
- 124 discovery (OR = 1.7, 95% CI 1.4-2.0, p = 2.5e-9, Fig 2A) and validation (OR = 1.4, 95% CI 1.2-
- 125 1.6, p = 1.4e-7, Fig 2A) data sets. We observed even larger AD risk associations with
- 126 autoimmune disorders in the cohort study groups, where odds ratios were 2.0 (95% CI 1.7-2.4,
- 127 p = 7.0e-15, Fig 2A) and 1.6 (95% CI 1.4-1.9, p = 1.6e-13, Fig 2A) for UCSF and Stanford,
- 128 respectively. This consistent elevated risk across study designs and EHR systems highlights a
- 129 strong connection between autoimmunity and AD.
- 130 We divided our discovery and validation data into female- and male-only subsets to
- 131 determine if AD risk remained elevated within sex-specific groups and learn if the overall risk

132 association was primarily driven by women. In the female-only subsets of the case-control study 133 designs, we observed significantly greater odds of an AD diagnosis in women with autoimmune 134 disorders compared to control women at both UCSF (OR = 1.8, 95% CI 1.4-2.2, p = 4.1e-8, Fig 135 2B) and Stanford (OR = 1.3, 95% CI 1.1-1.5, p = 3.0e-3, Fig 2B). Similarly, among women in the 136 cohort study groups, we observed significantly greater AD risk in women with autoimmune 137 disorders at UCSF (OR = 1.8, 95% CI 1.5-2.2, p = 4.9e–9, Fig 2B) and at Stanford (OR = 1.4, 138 95% CI 1.2-1.7, p = 1.2e-5, Fig 2B). There were also strong associations between autoimmunity 139 and AD in the male-only subsets. In the case-control study groups, men with autoimmune 140 disorders had significantly greater AD risk compared to control men across UCSF and Stanford 141 studies (UCSF OR = 1.5, 95% CI 1.1-2.0, p = 0.014; Stanford OR = 1.8, 95% CI 1.4-2.3, p = 142 8.2e-7; Fig 2B). The results in the cohort study groups agreed (UCSF OR = 2.5, 95% CI 1.7-3.6, 143 p=1.3e-7; Stanford OR = 2.3, 95% CI 1.8-3.0, p = 2.0e-11; Fig 2B), highlighting higher risk in 144 men with autoimmune disorders compared to control men across both EHR systems. The 145 increased AD risk observed in both men and women with autoimmune disorders suggests that 146 increased AD risk conferred by autoimmunity is not driven solely by one sex. 147 148 AD prevalence is increased in the presence of autoimmune disorders, but women remain 149 the most affected 150 While autoimmunity associates with AD risk within both sexes, we next tested whether it 151 elevated risk more in one sex than the other. Furthermore, we wanted to determine if the 152 presence of autoimmunity diminishes the well-documented AD sex-disparity wherein women 153 tend to develop AD more often than men. To address these questions, we conducted an AD 154 prevalence analysis within the cohort study groups of our discovery and validation data sets. 155 Due to the smaller number of men compared to women in our data, we conducted 1:1 matching 156 of women to men based on demographic variables (see Methods) and computed AD prevalence

157 across sex and autoimmunity stratifications. In our discovery data set, women with autoimmune

158 disorders (N = 5,821) had the highest AD prevalence at 3.0%, followed by men with 159 autoimmune disorders (N = 5,821) at 1.9%, control women (N = 5,821) at 1.7%, and finally 160 control men (N = 5,821) at 0.79% (Fig 2C). While the absolute prevalence values were lower at 161 Stanford, likely due to younger patients being included in the cohort study group as a result of 162 censored age information (see Methods), there was a similar hierarchy in the validation data 163 set, where women with autoimmune disorders (N = 45.743) had the highest AD prevalence at 164 0.47%, followed by men with autoimmune disorders (N = 45,743) at 0.43%, control women (N = 165 45.743) at 0.31%, and control men (45.743) at 0.19%. As expected, the higher prevalence in 166 control women compared to control men (UCSF corrected p = 6.2e-5; Stanford corrected p =167 1.1e-3; Fig 2C) corroborates well-documented sex-disparities in AD. We then discovered that 168 women with autoimmune disorders exhibited a higher AD prevalence than men with 169 autoimmune disorders in the UCSF data set (corrected p = 9.9e-4). The AD prevalence 170 difference between autoimmunity patients of different sexes was roughly equal in magnitude to 171 the difference between control patients of different sexes (1.1% versus 0.91%), suggesting that 172 sex-disparities in AD remain present, even with autoimmunity conferring greater risk in both 173 sexes. The intersex comparison in autoimmune patients in the Stanford data set was not 174 significant (p = 0.4), but women with autoimmune disorders did exhibit a slightly higher AD 175 prevalence than the corresponding men, likely indicating that women continue to bear the most 176 risk for AD even when a significant immune perturbation like autoimmunity is at play.

177

178 Specific autoimmune disorder subtypes are associated with greater AD risk, driven by

179 *individual disorders*

Next, to determine if particular classes of autoimmune disorders are associated with AD risk
more than others, we divided the 26 autoimmune disorders into subtypes based on the organ
system each one primarily affects. This resulted in eight disease subtype categories:

musculoskeletal, gastrointestinal, dermatologic, systemic, vascular, hematologic, neurologic,

184	and endocrine (Fig 3A). We computed the AD odds ratios for individuals with these disease
185	subtypes in each of the case-control and cohort study designs across UCSF and Stanford data
186	sets. In the overall case-control and cohort study designs of the UCSF data set, autoimmune
187	disorders in the gastrointestinal (case-control OR = 6.1, 95% CI 2.7-14.6, corrected p=7.2e-6;
188	cohort OR = 2.5, 95% CI 1.4-4.7, corrected p=6.5e-3, Fig 3B), hematologic (case-control OR =
189	18.1, 95% CI 4.7-84.8, corrected p=2.3e-6; cohort OR = 4.5, 95% CI 1.8-13.4, corrected
190	p=3.6e-3, Fig 3B), endocrine (case-control OR = 2.8, 95% CI 1.8-4.4, corrected p=6.0e-6;
191	cohort OR = 1.9, 95% CI 1.4-2.6, corrected p =2.2e-4, Fig 3B), musculoskeletal (case-control
192	OR = 2.5, 95% CI 1.7-3.9, corrected p=2.7e-5; cohort OR = 2.0, 95% CI 1.5-2.8, corrected
193	p=4.7e-5), and dermatologic (case-control OR = 3.1, 95% CI 1.6-6.1, corrected p=1.2e-3; cohort
194	OR = 2.4, 95% CI 1.4-4.0, corrected p=2.6e-3) categories associated with increased risk for AD.
195	Systemic, vascular, and neurologic disease subtypes did not significantly associate with
196	increased AD, potentially because we were underpowered to detect risk associations for these
197	particular subtypes (Table S2).
198	Several of the autoimmune disorder groups that were significantly associated with AD risk in
199	the UCSF data set were validated by the Stanford data set in one or both study designs.
200	Gastrointestinal (case-control OR = 2.5, 95% CI 1.5-4.2, corrected p = 1.6e-3; cohort OR = 2.0,
201	95% CI 1.4-3.0, corrected p = 1.1e-3, Fig 3B), endocrine (cohort OR = 1.9, 95% CI 1.3-2.6,
202	corrected p = 1.4e-3, Fig 3B), musculoskeletal (case-control OR = 1.7, 95% CI 1.3-2.3,
203	corrected $p = 1.6e-3$; cohort OR = 1.5, 95% CI 1.2-1.8, corrected $p=1.0e-3$, Fig 3B), and
204	dermatologic (case-control OR = 2.9, 95% Cl 1.8-4.7, corrected p=1.7e-5; cohort OR = 1.6, 95% $(1.8-4.7, 1.8-4$
205	CI 1.2-2.2, corrected p = 2.6e-2, Fig 3B) disorders all conferred significantly more AD risk in
206	autoimmune patients compared to non-autoimmune controls in the Stanford EHR system.
207	Next, we investigated if specific autoimmune disorders were driving the larger subtype and
208	overall risk associations to determine if particular disorders were greater risk factors than others.

210	with AD risk across UCSF (case-control OR = 5.0, 95% CI 2.1-12.9, corrected p=4.7e-4; cohort
211	OR = 2.1, 95% CI 1.1-4.0, corrected p=0.050, Fig 3B, S3) and Stanford (case-control OR = 4.0,
212	95% CI 2.1-7.9, corrected p = 3.7e-5; cohort OR = 2.3, 95% CI 1.4-3.7, corrected p = 1.1e-3,
213	Fig 3B, S3) study groups. Other disorders that conferred increased AD risk in at least two study
214	groups across data sets included autoimmune thyroiditis, type 1 diabetes, and rheumatoid
215	arthritis. Autoimmune thyroiditis, in the endocrine category, exhibited an odds ratio of 3.0 (95%
216	CI 1.4-6.4, corrected p = 9.0e-3, Fig 3B, S3) in the case-control study group and 2.3 (95% CI
217	1.4-4.1, corrected p = 4.2e-3, Fig 3B, S3) in the cohort study group at UCSF, in addition to
218	being a risk factor in the cohort study group of the Stanford data set (OR = 2.4, 95% CI 1.3-4.7,
219	corrected p = 1.1e-2, Fig 3B, S3). Also in the endocrine category, type 1 diabetes was
220	significantly associated with increased AD risk in the UCSF case-control study group (OR = 2.8,
221	95% CI 1.6-4.9, corrected p=8.6e-4, Fig 3B, S3) while also associating with nominally significant
222	risk in the UCSF cohort study group (OR = 1.6, 95% CI 1.1-2.4, uncorrected p=0.02, Fig 3B,
223	S3). Furthermore, type 1 diabetes was a significant AD risk factor in the Stanford cohort study
224	group (OR = 1.8, 95% CI 1.2-2.7, corrected p=2.4e-2, Fig 3B, S3).
225	Validated drivers of risk like autoimmune thyroiditis and type 1 diabetes highlight a potential
226	link between immune-mediated endocrine dysfunction and later AD pathogenesis. In addition to
227	endocrine disorders, rheumatoid arthritis was the primary disease that conferred risk in the
228	musculoskeletal disease category, and it was a significant risk factor in both UCSF study groups
229	(case-control OR = 2.2, 95% CI 1.3-3.7, corrected p=1.1e-2; cohort OR = 2.1, 95% CI 1.4-3.2,
230	corrected p=8.8e-4, Fig 3B, S3) as well as in the Stanford cohort study group (OR = 1.4, 95% CI
231	1.1-1.9, corrected p = 3.9e-2, Fig 3B, S3), with nominal significance in the Stanford case-control
232	study group (OR = 1.5, 95% CI 1.0-2.3, <i>uncorrected</i> p = 2.9e-2, Fig 3B, S3).
233	

234 AD risk from disease subtypes exhibits variable sex-specific effects

235 Next, we stratified the disease subtype and individual disease analyses by sex to determine if 236 any particular risk association was driven more by one sex compared to the other. Some 237 disease subtypes were fairly constant in exhibiting what appeared to be sex-specific risk 238 signals. For example, the endocrine category of disorders was predominantly significant among 239 women, exhibiting a significant AD risk effect in the female UCSF study groups (case-control 240 OR = 2.7, 95% CI 1.6-4.7, corrected p = 8.4e-4; cohort OR = 1.8, 95% CI 1.3-2.7, corrected p = 241 8.7e-3, Fig S2) and the female Stanford cohort study group (cohort OR = 1.8, 95% CI 1.2-2.8,242 corrected p = 0.04). In the dermatologic category, male-specific AD risk was higher than that of 243 the female-specific comparison in the majority of study groups. In the UCSF cohort study group, 244 men with dermatologic autoimmune disorders exhibited an odds ratio of 1.5 (95% CI 1.4-9.3, 245 corrected p=0.04, Fig S2), while women exhibited an odds ratio of 2.0 that was insignificant 246 after multiple testing correction (95% CI 1.1-3.8, corrected p=0.20, Fig S2). Similarly, in both 247 Stanford study groups, men with dermatologic autoimmune disorders were at greater AD risk 248 than controls (case-control OR = 7.8, 95% CI 3.4-18.5, corrected p=4.3e-7; cohort OR = 2.6, 249 95% CI 1.5-4.7, corrected p=1.9e-3, Fig S2) compared to women (case-control OR = 1.6, 95% 250 CI 0.9-3.0, corrected p = 0.94; cohort OR = 1.2, 95% CI 0.8-1.8, corrected p = 3.5, Fig S2). 251 Interestingly, in the case-control study group at UCSF, we also observed increased female-252 specific AD risk conferred by dermatologic autoimmune disorders (OR = 6.4, 95% CI 2.4-18.3, 253 corrected p=4.4e-4, Fig S2), perhaps indicating variable sex-specific effects for this category of 254 diseases. Similarly, we observed strong female-specific AD risk conferred by gastrointestinal 255 conditions in our discovery data set (case-control OR = 11.8, 95% CI 4.2-37.1, corrected 256 p=1.0e-6; cohort OR = 2.9, 95% CI 1.5-6.0, corrected p=6.5e-3, Fig S2), only to detect strong 257 male-specific AD risk from these conditions in our validation data set (case-control OR = 3.4, 258 95% CI 1.4-8.5, corrected p=4.0e-2; cohort OR = 3.3, 95% CI 1.6-7.5, corrected p=4.8e-3, Fig. 259 S2). These findings warrant more investigation into the factors influencing the direction of sex-260 specificity for these disorder classes.

261 Clear sex-specific differences in the risk conferred by individual autoimmune disorders were 262 harder to elucidate given a lack of power after stratifying by both sex and disorder (Table S2). 263 We nonetheless were able to identify significant female-specific AD risk conferred by 264 autoimmune thyroiditis in the cohort study groups of our two data sets (UCSF cohort OR = 2.4, 265 95% CI 1.3-4.5, corrected p=1.5e-2; Stanford cohort OR = 2.5, 95% CI 1.2-5.4, corrected 266 p=3.1e-2, Fig S4), likely driving the female-specific risk in the endocrine category of diseases. 267 Several other diseases increased AD risk significantly across some study groups, but not across 268 others (Fig S4) or exhibited different directions of sex-specific effects across study groups (Fig 269 S4). This again highlights the need for more studies of sex differences in the interaction 270 between the autoimmunity and AD in the future.

271

272 Sensitivity Analyses

We performed several sensitivity analyses to address the potential presence of confounders in 273 274 EHR data and test the robustness of the risk associations we identified. The sensitivity analyses 275 were performed in the discovery data set alone, as we wanted to verify the risk associations we 276 saw in the smaller UCSF study groups before performing further validations in the Stanford 277 study groups. Our first sensitivity analysis was to implement an age cutoff in our study designs 278 to quantify AD risk due to autoimmunity in two older sub-populations of individuals. The first 279 cutoff only included individuals in the study groups that had reached an age of 65 years or older. 280 When comparing autoimmune patients to non-autoimmune controls in this >65 data set, we 281 observed an AD odds ratio of 1.6 (95% CI 1.4-2.0, p=9.7e-9) in the case-control study group 282 and 2.0 (95% CI 1.6-2.4, p=1.7e-14) in the cohort study group (Table S3). Raising the cutoff to 283 80 years of age or older also resulted in a strong AD risk association with autoimmune disorders 284 (case-control OR = 1.7, 95% CI 1.4-2.2, p=1.7e-6; cohort OR = 2.4, 95% CI 1.8-3.1, p=1.8e-12, 285 Table S3), indicating that our signal was robust to the age range of patients in our discovery 286 data set.

287 Next we performed a sensitivity analysis to address possible confounder and collider effects that healthcare utilization can cause in EHR systems, since these effects can exaggerate 288 289 or attenuate differences between exposure and outcome groups. In addition to matching on 290 demographic variables (see Methods), we matched individuals based on the similarity of the 291 length of time between their first and last hospital visit date. After conducting this matching and 292 recomputing odds ratios in each study group, autoimmune disorders still associated with 293 increased risk for AD (case-control OR = 1.3, 95% CI 1.1-1.5, p = 6.0e-3; cohort OR = 1.4, 95% 294 Cl 1.2-1.7, p = 5.2e-6, Table S3). Matching on each patient's frequency of visits per year also 295 resulted in consistent increased risk associations between autoimmune disorders and AD (case-296 control OR = 1.3, 95% CI 1.1-1.6, p = 3.7e-4; cohort OR = 1.5, 95% CI 1.3-1.7, p = 2.0e-6, 297 Table S3), highlighting the connection between autoimmunity and AD at the clinical level even 298 when adjusting for different healthcare utilization measures.

299 In the final sensitivity analysis, we recomputed odds ratios in each study group without 300 including age at death as a variable in matching, to verify that leaving it out of the matching 301 criteria did not significantly alter results (see Matching and Finalization of Study Groups in 302 Methods). This resulted in an AD odds ratio of 1.3 (95% CI 1.1-1.5, p = 7.1e-4) in the case-303 control study group and 2.1 (95% CI 1.8-2.5, p = 4.7e-17) in the cohort study group (Table S3), 304 indicating that leaving total lifespan information out of the matching criteria preserves risk signal. 305 Several disease subtypes and individual disease associations seen in the main UCSF analysis 306 were present in many, if not all, of these sensitivity conditions, including the increased AD risk 307 due to endocrine, gastrointestinal, and musculoskeletal disorders driven by inflammatory bowel 308 disease, type 1 diabetes, autoimmune thyroiditis, and rheumatoid arthritis (Table S3).

309

310 Sex, but not autoimmunity, associates with accelerated AD onset over time

311 In addition to examining the presence or absence of AD in autoimmunity patients through our

312 risk analyses, we also tested whether autoimmune disorders influence the timing of AD onset.

313 We hypothesized that autoimmune disorders would decrease the age at which people are diagnosed with AD, potentially due to the early presence of chronic inflammation that 314 315 autoimmune disorders bring about. We constructed new longitudinal cohorts for this analysis 316 consisting only of AD patients with and without autoimmune disorders. This resulted in 292 317 autoimmune patients with 292 matched controls at UCSF (N = 584 total AD patients, Fig 4A), 318 and 392 autoimmune patients with 392 matched controls at Stanford (N = 784 total AD patients, 319 Fig 4A). We first compared the distributions of AD diagnosis age among patients. In the UCSF 320 longitudinal cohort, the average age at which autoimmune patients were diagnosed with AD was 321 75.6 years, compared to the controls at 76.5 years (Fig S5A). In the Stanford longitudinal 322 cohort, the average AD diagnosis age was 81.8 years in autoimmune patients compared to 82.4 323 years in controls (Fig S5A). While the AD diagnosis age was lower in autoimmune patients in 324 each data set, the differences between age distributions were not significant in either case 325 (UCSF p = 0.11, Stanford p = 0.17, Fig S5A), likely because of relatively small sample size 326 (Table S2). The 0.6- to 1-year difference in diagnosis age we observed is nonetheless striking, 327 given the often rapid symptomatic decline (21) of individuals with AD. Even being diagnosed 328 with AD half a year earlier could be extremely impactful for patients and their quality of life. 329 We also observed differences in AD onset age when we stratified individuals both by sex and 330 autoimmune disorder. Starting in the UCSF longitudinal cohort, women with autoimmune 331 disorders exhibited significantly younger AD onset ages (mean 75.0 years, Fig 4B) compared to 332 men with autoimmune disorders (mean 76.7 years, p = 0.017, Fig 4B). Similarly, control women 333 exhibited significantly younger AD onset ages (mean 76.0 years, Fig 4B) compared to control 334 men (mean 77.7 years, p = 0.011, Fig 4B). Comparing autoimmune patients to matched 335 controls within each sex did not reveal younger onset ages (female p = 0.19, male p = 0.28, Fig 336 4B), likely indicating that sex plays a larger role in the timing of AD onset. Results from the 337 Stanford longitudinal cohort all agreed directionally with the UCSF results, however with 338 insignificant results (Fig 4B).

351	Discussion
350	
349	into sex as an influential variable in the timing of AD onset are needed to resolve this mismatch.
348	developing AD earlier (HR = 1.2, 95% CI 1.0-1.4, p = 0.02, Fig S5B). Better powered analyses
347	S5B), while in the Stanford longitudinal cohort it was significantly associated with risk of
346	longitudinal cohort trended toward being protective (HR = 0.85, 95% CI 0.7-1.0, p = 0.064, Fig
345	given disagreement between UCSF and Stanford data sets. Being male in the UCSF
344	corroborating the results from the distributional analysis. The hazard effects of sex were unclear
343	1.1, 95% CI 1.0-1.3, p = 0.16; Stanford HR = 1.0, 95% CI 0.9-1.2, p = 0.5, Fig S5B),
342	significantly alter the hazard of individuals developing AD over time (UCSF Hazard Ratio (HR) =
341	sex and autoimmunity presence as covariates. Having an autoimmune disorder did not
340	stratifications varied over time. We used a Cox proportional hazard model for the analysis with
339	Finally, we performed a survival analysis to determine if the risk of developing AD in different

352 We have shown that autoimmune disorders are associated with increased risk of being 353 diagnosed with AD in case-control and cohort study designs across two different EHR systems, 354 suggesting that autoimmunity is a significant risk factor for AD. We observed a clear and strong 355 increased risk signal in our study groups, both overall and in female- and male-specific subsets of our data, indicating that autoimmunity increases AD risk regardless of sex. Interestingly, in 356 357 our AD prevalence analysis, women with autoimmune disorders exhibited increased AD 358 prevalence compared to men with autoimmune disorders, indicating that both autoimmunity and 359 sex play crucial roles in AD risk.

We observed specific subtypes of autoimmune disorders that conferred AD risk in patients. These particular classes of disorders suggest the presence of shared pathophysiology between particular autoimmunity subtypes and AD. For example, metabolic dysfunction has been highlighted in previous AD pathogenesis studies (22), so it is possible that metabolic pathways

364 exist that link endocrine autoimmune disorders, which greatly affect metabolism, and AD 365 pathogenesis. Similarly, there have been documented links between changes in the gut-brain 366 axis (23) and microbiome (24) that are associated with AD in previous work, which could relate 367 AD pathogenesis to pathways involved in gastrointestinal autoimmune disorders. Depending on 368 the autoimmune disorder subtype and individual autoimmune disorders we analyzed, we also 369 observed some sex-specific risk associations, highlighting that autoimmune disorders that fall 370 under the category of certain physiological systems may manifest differently in women 371 compared to men. This can provide more insight into the specific mechanisms that may go awry 372 to cause or exacerbate AD in particular sexes.

373 Our findings validate and provide new insights on previous work. Recently, Miller et al. (25) 374 found increased prevalence of inflammatory bowel disease in a small cohort of late-onset AD 375 cases which we have validated in much larger clinical data sets. Furthermore, a study of the 376 Swedish National Patient Register (26) highlighted increased incidence rates of several 377 autoimmune disorders including hypothyroidism/thyroiditis, type 1 diabetes, Addison's disease, 378 Sjögren's syndrome, and pernicious anemia in dementia patients. We were able to corroborate 379 several of these signals with our analysis; we also found type 1 diabetes and a form of 380 thyroiditis as significant modifiers of risk. We further built upon these findings by analyzing 381 disease subtypes to identify particular physiological systems that may be more involved in AD 382 pathogenesis, and we conducted extensive age of onset and sex-specific analyses to robustly 383 characterize AD risk in autoimmune individuals. Finally, a recent study (27) in individuals of the 384 UK Biobank indicated increased hazard ratios for four major autoimmune disorders (rheumatoid 385 arthritis, multiple sclerosis, psoriasis, and inflammatory bowel disease) in a longitudinal cohort. 386 Our results expand on this study by investigating several more autoimmune disorders and sex 387 as a biological variable in the risk analyses. Compared to the individuals in the UK Biobank and 388 Swedish studies, our population of patients was also more diverse, suggesting generalizability

of the increased risk association between autoimmune disorders and AD across diversepopulations of humans.

By using two different study designs (case-control and cohort) in both a discovery and validation data set in all of our analyses, we were further able to show robust associations while combating common problems of selection bias (28), data inaccuracies (29), and confounding that can be common in EHR studies. Our workflow can be further applied not only to autoimmune disorders and their risk relationship to other neurological diseases, but to any two disease types of interest that can be captured in an EHR data system.

397 The current study has several limitations that should be considered when evaluating our 398 results. First, the groupings used for the disease subtype analysis are imperfect. Since the exact 399 underlying mechanism of many of the autoimmune disorders we investigated remains unknown, 400 grouping by physiological system enabled us to study these diseases in aggregate, but it 401 reflects only one dimension along which each autoimmune disorder is related to the others. 402 Another caveat is the presence of censored death information in the validation data set. This 403 may have resulted in the incorporation of younger patients in the Stanford study groups who 404 had yet to develop either AD or a later-onset autoimmune disorder, and as such, this may have 405 deflated the odds ratios in the Stanford study groups. It is possible that this led to less 406 agreement in risk associations between UCSF and Stanford particularly for the subtype and 407 individual disorder analyses. While we matched individuals based on lifespan and/or birth year 408 within each of our study groups, future work could include age-matching between discovery and 409 validation data sets to enhance similarity of comparisons even further. Finally, the stratified 410 analyses we conducted were less likely to yield consistent significant results across sites and 411 study designs. Much of this was likely the result of reduced power due to the small sample sizes 412 in the stratified cohorts. This also occasionally yielded very high odds ratios and large confidence intervals in our analyses. Nonetheless, many of these analyses highlight promising 413 414 specific hypotheses for further validation and molecular characterization.

415 In summary, autoimmune disorders are strong risk factors for AD that act across sexes. This 416 study illustrates the usefulness of EHRs for cross-trait analyses, and it also informs further 417 mechanistic hypotheses about the exact molecular interfaces that may go awry in the interaction 418 of the immune and nervous systems to promote AD pathogenesis. Further risk factor analyses 419 for debilitating neurological conditions such as AD will empower clinicians to inform patients of 420 their risk profiles for different diseases. Ultimately, deeper understanding of these connections 421 between risk and disease can empower patients themselves to make lifestyle changes or take 422 relevant treatments that can help avoid or delay disease. Our results highlight several future 423 directions for further understanding of the risk relationship between autoimmune disorders and 424 AD. First, guantifying how AD risk varies based on differing levels of autoimmune disorder 425 severity and duration is needed. We hypothesize that more severe forms of autoimmune 426 disorders may confer the most AD risk, and perhaps treatments to alleviate more severe 427 disorders may decrease risk. Additionally, taking into account the chronic nature and onset age 428 of many autoimmune disorders may shed more light on the temporal dynamics of the two traits 429 interacting throughout the lifespan. Finally, integrating clinical risk analyses with other data 430 modalities, such as genetics or proteomics will provide more molecular insight into the link 431 between AD and autoimmune disorders and help to fully elucidate the basis for the strong risk 432 seen at the phenotypic level in human populations.

433

434 Methods

435 Sex as a Biological Variable

We accounted for sex as a biological variable by performing all analyses in female- and malespecific subsets of our original study groups. This allowed us to test if any risk associations differed by sex, and if particular autoimmunity subtypes or individual disorders were driving AD risk in a particular sex. We filtered out individuals with an unknown sex from our UCSF study

groups. Due to differences in encoding sex within the UCSF and Stanford EHR systems, there

441 were a small number of individuals (0.02% of the total) with an unknown sex that were included

in the Stanford cohort data set. These individuals were not included in any sex-specific

- 443 analyses.
- 444

445 Study Group Identification

446 Autoimmune Disorder, Alzheimer's Disease, and Healthy Control Patient Identification

447 We identified 26 autoimmune disorders of interest (Table S1) for our study based on prior 448 literature and prevalence in the general population. Individuals with each autoimmune disorder 449 were identified by string-matching autoimmune disorder names (Table S4) with billing concepts. 450 Concepts were subsequently standardized for use in the UCSF EHR database (30) which is 451 based on the Observational Medical Outcomes Partnership (OMOP) Common Data Model 452 (CDM) and primarily uses Systemized Nomenclature of Medicine (SNOMED) concept 453 encodings. All standardized billing concepts were examined by UCSF rheumatologists to 454 confirm validity and relevance of each concept to each autoimmune disorder of interest. We 455 compiled a final list of 878 autoimmune billing concepts (Table S5). We identified patients who 456 had these concepts present in their UCSF medical record to construct our discovery data set, 457 and used identical concepts to identify patients from the Stanford EHR database for our 458 validation data set. We identified patients with AD in a similar manner to autoimmune disorder 459 patients after string-matching AD terms to concepts (Table S6) and checking for billing concept 460 occurrence in each patient record in the UCSF and Stanford systems. We only included AD 461 billing concepts related to late-onset or sporadic AD, as early-onset AD is thought to have 462 distinct etiology and stronger genetic components (31). Additional demographic data from the 463 UCSF and Stanford EHR systems was collected on patients including date of birth, date of 464 death (if available), self-reported race, self-reported ethnicity, and sex. We also gathered

465 healthcare utilization statistics on patients, including number of doctor's visits, total number of466 unique diagnoses, and first and last medical visit date.

467 We identified healthy control individuals without autoimmune disorders to compare to the 468 autoimmune patient groups from the UCSF and Stanford databases. To do this, we searched 469 for patients *without* any of the 878 finalized autoimmune disorder billing concepts present in 470 their records, and we additionally removed individuals from the healthy control group who had 471 concepts that were similar to any of the 878 finalized autoimmune concepts. For example, an 472 individual who had the billing concept "family history of Celiac disease" in their EHR but did not 473 have a more specific Celiac disease billing concept identifying a personal diagnosis of Celiac 474 disease would have been excluded. Similarly, several billing concepts that were too general to 475 pertain specifically to an autoimmune disorder (e.g. kidney disease) but that represented a 476 serious condition were excluded from the healthy controls. For our cohort study design, we 477 matched the healthy controls to autoimmune disorder patients based on criteria further 478 described in the Matching and Finalization of Study Groups section of the Methods. 479 To identify a population of non-AD healthy controls to compare to our AD patient group, we 480 searched for patients without any AD billing concepts in their records and matched them with 481 AD cases based on demographic factors. To clarify some terminology, the control individuals 482 that were matched to autoimmune disorder cases will be referred to as the "non-autoimmune 483 controls" going forward, whereas the control individuals that were matched to AD cases will be 484 referred to as the "non-AD controls". These are two separate groups of controls, but they may 485 have overlap in individuals as someone without both an autoimmune disorder and AD might be

in both control groups. Additionally, someone in one of the disease groups may be in a controlgroup for the other disease. For example, an AD patient might show up in the non-autoimmune

488 control group, since the requirement to be in that group is not having an autoimmune disorder.

489 Data Cleaning and Quality Control

490 Our data cleaning pipeline involved several steps. First, we performed quality control to remove 491 any individuals with missing demographic information in the self-reported race, self-reported 492 ethnicity, sex, and birth year categories from consideration for our disease and healthy control 493 groups in the UCSF data set. Due to differences in encoding some of this demographic 494 information between UCSF and Stanford EHR systems, a small number of individuals with 495 unknown demographic values were included in the Stanford data set (see Sex as a Biological 496 Variable), but each individual with an "unknown" demographic field was similarly matched with 497 another Stanford individual with an "unknown" value, removing any issues comparing people 498 without matching information. In the UCSF study groups, we also required individuals to have a 499 valid reported age at death, as this allowed us to compare individuals by total lifespan. We 500 restricted individuals to be between 30 and 90 years of age at their death in these groups. In the 501 Stanford study groups, there was a greater degree of censored death information such that 502 including lifespan information in matching would have extremely limited our study group sizes. 503 so we did not enforce this constraint. We verified that leaving out lifespan as a matching 504 variable in the Stanford groups did not significantly alter overall risk signals, so we felt confident 505 leaving it out of our validation study group criteria (See Sensitivity Analyses in Results). It is 506 likely that, because of censored data being included in the Stanford data sets, the increased risk 507 associations we saw in our analyses would be even stronger in real life (see Discussion). In 508 addition to quality control on demographics, we also removed individuals who had zero hospital 509 visits or whose first and last visit dates were the same.

We next determined 1) who in the autoimmune disorder patient groups and corresponding non-autoimmune control groups had an AD diagnosis, and 2) who in the AD patient groups and corresponding non-AD control groups had an autoimmune disorder diagnosis. Within our autoimmune/AD disease groups and respective healthy control groups, different individuals were demarcated with their assigned "person ID" following OMOP conventions. We then determined which person IDs of one group overlapped with the person IDs of another group.

For example, to discover which autoimmune patients and non-autoimmune controls had an AD diagnosis, we determined which of the person IDs of our AD patient group overlapped with the person IDs of the autoimmune and non-autoimmune groups. In a similar manner, we determined which AD patients and which non-AD controls had an autoimmune diagnosis by overlapping the person IDs of our autoimmune patient group with the AD and non-AD person IDs.

522 We also identified the relative dates of AD and autoimmunity diagnoses for patients. To 523 focus on the effect of autoimmunity on AD, we did not consider individuals who had an AD 524 diagnosis prior to their autoimmune disorder diagnosis. Specifically in the UCSF data set, we 525 computed several metrics for each individual to aid the matching of autoimmune or AD patients 526 to their respective controls when performing different sensitivity analyses. These metrics 527 included each individual's age when they died, the total length of the UCSF EHR record (last 528 visit date - first visit date), and the frequency of doctor's visits per year 529 To understand which autoimmune disorder subtypes might be driving AD risk, we grouped 530 the 26 autoimmune disorders of interest into 8 distinct subtype categories (Table S1 and Fig 3A) 531 and assigned patients into categories based on which autoimmune disorder(s) they had. If a 532 patient had multiple autoimmune disorders (UCSF N = 2,378 patients, Stanford N = 37,332533 patients) across different subtype categories, they were counted once within each subtype risk 534 association analysis, and therefore could be represented in more than one analysis. 535 Study Designs, Matching, and Finalization of Study Groups 536 To mitigate selection bias and ensure robustness of results, we examined the risk of receiving

537 an AD diagnosis following an autoimmune disorder diagnosis using two study designs in each of

538 our EHR data sets: a retrospective case-control study with AD patients and non-AD matched

539 controls, and a retrospective cohort study with autoimmune disorder patients and non-

autoimmune matched controls. We performed 1:1 matching of patients to controls for each

541 study group using propensity scoring on each individual's birth year, sex, self-reported race, and

542 self-reported ethnicity. We also matched on lifespan in the UCSF study groups (See Data 543 Cleaning). We enforced exact matches between patients and controls in the categories of sex, 544 self-reported race, and self-reported ethnicity. In our main analysis and throughout follow-up 545 sensitivity analyses, we ensured high-quality matching by verifying that the average absolute 546 standardized mean error between each matched pair was less than 0.1. We conducted final 547 guality control in both study groups of our main and sensitivity analyses by removing any 548 matched pairs of individuals where a control individual was diagnosed with AD prior to the 549 matched disease case being diagnosed with an autoimmune disorder. All matching was 550 performed using the nearest neighbor method of the Matchlt package (4.5.3) in R. After 551 matching and cleaning, we were left with four "study groups": a case-control and cohort study 552 group from UCSF, and a case-control and cohort study group from Stanford.

553

554 AD Risk Analysis in Case-Control and Cohort Study Groups

555 In order to enable comparison across the different study designs, we computed odds ratios to 556 guantify the risk of being diagnosed with AD in autoimmune disorder patients compared to non-557 autoimmune controls. Across each of the study groups, we computed odds ratios at three 558 levels: 1) across all autoimmune disorders combined, 2) across autoimmunity subtypes, and 3) 559 across individual autoimmune disorders. At each of these three levels, we repeated the analysis 560 in a sex-stratified manner to explore if risk was sex-specific. All odds ratios were computed 561 using a Fisher exact test on contingency tables of AD/autoimmunity patients, and we used the 562 oddsratio.fisher function of the epitools package (version 0.5-10.1) in R to compute these 563 statistics.

564 To account for multiple hypothesis testing, we used Bonferroni corrections for each odds 565 ratio analysis. For the disease subtype risk analysis, we corrected p-values within each overall 566 or sex stratification group (e.g., a correction factor of 8 for the 8 disease subtype comparisons). 567 For the specific disorder risk analysis, we performed a within-disorder-subtype p-value

correction, to evaluate which specific conditions within an autoimmune disorder subtype group
had significant subtype effects. This meant the correction factor for a particular disorder
comparison was determined by the number of conditions within that particular disorder's
subtype category (e.g., p-values for each autoimmune disorder in the endocrine subgroup were
corrected by a factor of 4, due to the endocrine subgroup being comprised of 4 diseases).

573

574 AD Prevalence Calculations in Cohort Study Groups

575 We calculated the prevalence of AD in patients with autoimmune disorders compared to 576 matched controls in a sex-stratified manner. To ensure that a difference in prevalence was not 577 due to underlying demographic differences between female and male individuals, we took the 578 cohort study groups across UCSF and Stanford and matched the smaller sample size of male 579 individuals to female individuals based on birth year, self-reported race, and self-reported 580 ethnicity, while matching additionally on lifespan in the UCSF study groups. Again, we used 581 exact matching on self-reported race and self-reported ethnicity while using propensity score 582 matching on the remaining variables. We then calculated the percentage of people with AD in 583 each stratification: female individuals with autoimmune disorders, male individuals with 584 autoimmune disorders, female non-autoimmune control individuals, and male non-autoimmune 585 control individuals. To obtain a 95% confidence interval for each prevalence statistic, we 586 bootstrapped the data 1,000 times. We again used a Fisher's exact test to compute significance 587 of prevalence differences among stratifications.

588

589 Longitudinal AD Onset Analysis

590 To understand the effect of autoimmunity on the risk of AD diagnosis over time, we conducted a 591 longitudinal age of onset analysis. For this, we constructed new longitudinal study groups from 592 the UCSF and Stanford EHR systems consisting of individuals with both an autoimmune 593 disorder and AD from our cohort study designs. These longitudinal cohorts also passed our data

594 guality control pipeline. We matched the autoimmunity patients with AD to non-autoimmune 595 individuals with AD from the larger UCSF and Stanford background databases. The same 596 variables used in matching for the main odds ratio analysis were also used here. The age of AD 597 onset for each individual in each longitudinal study group was then calculated by taking the 598 difference in time between a person's birth year and the first appearance of an AD billing 599 concept in the person's medical record. The Mann–Whitney U test and Cox proportional hazard 600 modeling conducted in these study groups was performed using the stats (v4.1.3) and 601 survival/survminer (v3.5-5/0.4.9) packages, respectively, in R. 602 603 **Statistics** 604 We used Fisher's exact test for all odds ratio calculations and for comparisons in our AD 605 prevalence analysis. We also used a Mann-Whitney U test for a non-parametric comparison of 606 distributions in our longitudinal AD onset analysis. Bonferroni corrections were applied to p 607 values throughout this study; these are denoted by the use of "corrected" or "adjusted" p values. 608 609 Study Approval 610 All analysis of University of California, San Francisco and Stanford University electronic health 611 record data was performed under the approval of the Institutional Review Boards from 612 University of California, San Francisco and Stanford University, respectively. All clinical data 613 were de-identified and written informed consent was waived by the institutions. 614

615 Data Availability

616 Individual patient data is not publicly available due to patient data sharing privacy. Code not

617 limited by patient data sharing permissions can be found at

618 https://github.com/gramey02/AD_AID_Project. All patient and demographic data curation from

619 the UCSF and Stanford EHR systems was performed using Microsoft SQL server and the DBI

620	(v1.1.3) and odbc (1.3.4) packages in R. Discovery data was last curated from the UCSF OMOP
621	database on August 4th, 2023, and validation data was last curated from the Stanford OMOP
622	database on December 12th, 2023. Data cleaning, matching, and analysis steps were
623	conducted using R version 4.1.3, and plots were created with the ggplot2 package (v3.4.2).
624	Values for all data points in graphs are reported in the Supporting Data Values file.
625	
626	Author Contributions
627	A.T., Z.M., M.S, and G.D.R. conceptualized this research project. G.D.R. investigated and
628	curated all UCSF data and performed all UCSF statistical and computational analysis. T.P.
629	performed all Stanford validation steps, including data curation and statistical/computational
630	analysis. M.Y. provided valuable clinical input on EHR methodology and clinical billing codes.
631	G.D.R. and A.T. wrote the manuscript, and G.D.R. created visualizations. J.A.C. and M.S.
632	provided mentorship, review/editing of writing, and funding for the work. I.A., N.A., T.M., T.O.,
633	and S.W. provided expertise and manuscript feedback.
634	
635	Acknowledgements
636	We would like to thank all of the members of J.A.C.'s, M.S.'s, and N.A.'s labs for all of their
637	feedback throughout this work. We acknowledge our funding sources, including NIA
638	R01AG060393, NIAMS P30 AR070155, F30 Fellowship 1F30AG079504-01, and the UCSF
639	Discovery Fellows. We would also like to acknowledge the use of the UCSF Information
640	Commons and UCSF Research Analysis Environment computational research platforms.
641	Through these platforms, the project was supported by the National Center for Advancing
642	Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1
643	TR001872. Its contents are solely the responsibility of the authors and do not necessarily
644	represent the official views of the NIH.

645 **References**

- 2024 Alzheimer's disease facts and figures. *Alzheimers Dement J Alzheimers Assoc*.
 2024;20(5). https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
- 648 2. 2023 Alzheimer's disease facts and figures. *Alzheimers Dement J Alzheimers Assoc*.
 649 2023;19(4):1598-1695. doi:10.1002/alz.13016
- Jack CR, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement J Alzheimers Assoc*. 2018;14(4):535-562.
 doi:10.1016/j.jalz.2018.02.018
- 653 4. Revised Criteria for Diagnosis and Staging of Alzheimer's | AAIC. Revised Criteria for
 654 Diagnosis and Staging of Alzheimer's | AAIC. Accessed March 24, 2024.
 655 https://aaic.alz.org/diagnostic-criteria.asp
- 5. Van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. *N Engl J Med*.
 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
- Huang LK, et al. Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update. J
 Biomed Sci. 2023;30(1):83. doi:10.1186/s12929-023-00976-6
- 660 7. Newcombe EA, et al. Inflammation: the link between comorbidities, genetics, and
 661 Alzheimer's disease. *J Neuroinflammation*. 2018;15:276. doi:10.1186/s12974-018-1313-3
- 8. Princiotta Cariddi L, et al. Alzheimer's Disease: From Immune Homeostasis to
 Neuroinflammatory Condition. *Int J Mol Sci*. 2022;23(21):13008.
 doi:10.3390/ijms232113008
- 665 9. Laurent C, et al. Hippocampal T cell infiltration promotes neuroinflammation and cognitive
 666 decline in a mouse model of tauopathy. *Brain*. 2017;140(1):184-200.
 667 doi:10.1093/brain/aww270
- Chen X, Holtzman DM. Emerging roles of innate and adaptive immunity in Alzheimer's
 disease. *Immunity*. 2022;55(12):2236-2254. doi:10.1016/j.immuni.2022.10.016
- 11. Ahmed ME, et al. Co-Localization of Glia Maturation Factor with NLRP3 Inflammasome and
 Autophagosome Markers in Human Alzheimer's Disease Brain. *J Alzheimers Dis*.
 2017;60(3):1143-1160. doi:10.3233/JAD-170634
- Rogers J, et al. Complement activation by beta-amyloid in Alzheimer disease. *Proc Natl Acad Sci U S A*. 1992;89(21):10016-10020.
- 13. Walker DG, McGeer PL. Complement gene expression in human brain: comparison
 between normal and Alzheimer disease cases. *Mol Brain Res.* 1992;14(1):109-116.
 doi:10.1016/0169-328X(92)90017-6
- 678 14. Berg A, et al. Reduced removal of synaptic terminals from axotomized spinal motoneurons
 679 in the absence of complement C3. *Exp Neurol*. 2012;237(1):8-17.
 680 doi:10.1016/j.expneurol.2012.06.008

- 15. Dou DR, et al. Xist ribonucleoproteins promote female sex-biased autoimmunity. *Cell*.
 2024;187(3):733-749.e16. doi:10.1016/j.cell.2023.12.037
- 683 16. Ortona E, et al. Sex-based differences in autoimmune diseases. *Ann Ist Super Sanita*.
 684 2016;52(2):205-212. doi:10.4415/ANN_16_02_12
- Belonwu SA, et al. Sex-Stratified Single-Cell RNA-Seq Analysis Identifies Sex-Specific and
 Cell Type-Specific Transcriptional Responses in Alzheimer's Disease Across Two Brain
 Regions. *Mol Neurobiol*. 2022;59(1):276-293. doi:10.1007/s12035-021-02591-8
- 18. Lopez-Lee C, et al. Sex Differences in Neurodegeneration: The Role of the Immune System
 in Humans. *Biol Psychiatry*. 2022;91(1):72-80. doi:10.1016/j.biopsych.2021.01.002
- 19. Natri H, et al. The Pregnancy Pickle: Evolved Immune Compensation Due to Pregnancy
 Underlies Sex Differences in Human Diseases. *Trends Genet*. 2019;35(7):478-488.
 doi:10.1016/j.tig.2019.04.008
- 693 20. Stang PE, et al. Advancing the Science for Active Surveillance: Rationale and Design for the
 694 Observational Medical Outcomes Partnership. *Ann Intern Med*. 2010;153(9):600-606.
 695 doi:10.7326/0003-4819-153-9-201011020-00010
- 696 21. Stages of Alzheimer's. Alzheimer's Disease and Dementia. Accessed March 24, 2024.
 697 https://alz.org/alzheimers-dementia/stages
- Caspersen C, et al. Mitochondrial Aβ: a potential focal point for neuronal metabolic
 dysfunction in Alzheimer's disease. *FASEB J*. 2005;19(14):2040-2041. doi:10.1096/fj.053735fje
- Marizzoni M, et al. A peripheral signature of Alzheimer's disease featuring microbiota-gut brain axis markers. *Alzheimers Res Ther*. 2023;15(1):101. doi:10.1186/s13195-023-01218-5
- 703 24. Ferreiro AL, et al. Gut microbiome composition may be an indicator of preclinical
 704 Alzheimer's disease. *Sci Transl Med*. 2023;15(700):eabo2984.
 705 doi:10.1126/scitranslmed.abo2984
- 706 25. Miller ZA, et al. Left-handedness, learning disability, autoimmune disease, and seizure
 707 history influence age at onset and phenotypical targeting of Alzheimer's disease [preprint].
 708 https://doi.org/10.1101/2022.12.17.22283307. Posted on medRxiv December 20, 2022.
- 26. Li X, et al. Dementia and Alzheimer's disease risks in patients with autoimmune disorders:
 Autoimmune disorders and dementia. *Geriatr Gerontol Int*. 2018;18(9):1350-1355.
 doi:10.1111/ggi.13488
- 712 27. Huang J, et al. Inflammatory Diseases, Inflammatory Biomarkers, and Alzheimer Disease.
 713 *Neurology*. 2023;100(6):e568-e581. doi:10.1212/WNL.00000000201489
- 28. Beesley LJ, Mukherjee B. Statistical inference for association studies using electronic health
 records: handling both selection bias and outcome misclassification. *Biometrics*.
 2022;78(1):214-226. doi:10.1111/biom.13400

- 29. Peskoe SB, et al. Adjusting for selection bias due to missing data in electronic health
- records-based research. *Stat Methods Med Res*. 2021;30(10):2221-2238.
- 719 doi:10.1177/09622802211027601
- 30. University of California, San Francisco, Academic Research Systems (2022). UCSF DeID
 CDW-OMOP. 2023-August. University of California, San Francisco. Dataset. Available
 through https://data.ucsf.edu/research/deid-data.
- 31. Wingo TS, et al. Autosomal recessive causes likely in early-onset Alzheimer disease. Arch
 Neurol. 2012;69(1):59-64. doi:10.1001/archneurol.2011.221

725 Figures & Figure Legends



726

727 Figure 1. Risk analysis framework and observational study designs. We take a top-down hierarchical 728 approach to calculate AD risk in autoimmune disorder patients based on two large electronic health record 729 (EHR) data sets. We compute odds ratios to assess if any autoimmune disorder diagnosis, a particular 730 autoimmune subtype diagnosis, or a specific autoimmune disorder diagnosis increases AD risk. We used 731 both a case-control and cohort study design to ensure robustness and reduce biases. For the case-control 732 study design, we first identified patients with the outcome of interest (an AD diagnosis, red) and then 733 determined which of the AD patients also had an autoimmune diagnosis (blue). We matched the AD 734 patients to non-AD controls using propensity score matching and gathered information on other 735 demographic variables for cases and controls. For the cohort study design, we identified patients with the 736 exposure first (an autoimmunity diagnosis, blue) and determined which of the exposed patients also had 737 an AD diagnosis (red). Demographic information was extracted and propensity score matching was used 738 to match autoimmune cases to non-autoimmune controls. We used these study structures to analyze data 739 from both the UCSF (discovery) and Stanford (validation) EHR databases. Dx = diagnosis



⁷⁴⁰ 741

742 Figure 2. Autoimmune disorders are associated with increased AD risk across study designs and 743 EHR data sets. A) Odds ratios quantifying AD risk in autoimmune patients versus non-autoimmune 744 controls. We observed increased odds of AD across both the UCSF (left) and Stanford (right) data sets, 745 and across case-control and cohort study groups within each data set, robustly highlighting greater AD risk 746 conferred by autoimmunity. B) AD risk in the female- and male-only subsets of each data set. Increased AD 747 risk was present in both sexes in each data set. C) AD prevalence calculated in the cohort study designs in 748 different sex and disorder strata. Confidence intervals were obtained by bootstrapping the data. AD 749 prevalence was higher in women with autoimmune disorders compared to all other groups in both the UCSF 750 (left) and Stanford (right) data.



751 752

753 Figure 3. Specific autoimmune disorder subtypes and individual diseases associate with 754 increased AD risk. A) Individual autoimmune disorders can be grouped into subtypes based on 755 physiological symptomatology. We used eight subtype groups in our analysis. B) Odds ratios 756 quantifying AD risk in patients with different autoimmune disorder subtypes and specific autoimmune 757 disorders compared to controls. Disorder subtypes are in bold, and the specific disorders that fall into 758 each subtype category are listed below. Only individual autoimmune disorders that were statistically 759 significant are pictured. The larger and darker the circle is, the greater the effect size and significance 760 of the odds ratio, respectively. N.S. = Not Significant after multiple testing correction



763 Figure 4. AD onset is accelerated in women, with potential acceleration 764 from autoimmune disorders. A) Study design for the longitudinal AD onset 765 analysis, conducted using data from the UCSF and Stanford EHR data sets. 766 B) Distributions of AD diagnosis age among individuals with and without 767 autoimmune diseases in the longitudinal cohorts, stratified by sex. Numbers 768 below stratifications are the mean age at diagnosis, and the black summary 769 lines highlight the mean and standard deviation of each distribution. Within 770 the autoimmune and control subgroups, women were diagnosed with AD at 771 a younger age than men, indicating that sex plays a large role in the age of 772 AD onset.

Tables 773

774 775 Table 1. UCSF and Stanford Study Group Demographics

	UCSF					Stanford			
Case-Control Study Design					Case-Control Study Design				
	Non-AD Controls	AD Patients	p value	SMD		Non-AD Controls	AD Patients	p value	SMD
N	3,906	3,906			N	6,646	6,646		
Sex (%)			1	< 0.001	Sex (%)			1	< 0.001
Female	2416 (61.9)	2416 (61.9)			Female	4,143 (62.3)	4,143 (62.3)		
Male	1,490 (38.1)	1,490 (38.1)			Male	2,503 (37.7)	2,503 (37.7)		
Unknown	0 (0.0)	0 (0.0)			Unknown	0 (0.0)	0 (0.0)		
Self-reported race (%)			1	< 0.001	Self-reported race (%)			1	<0.001
Asian	531 (13.6)	531 (13.6)			Asian	952 (14.3)	952 (14.3)		
Black or African American	232 (5.9)	232 (5.9)			Black or African American	315 (4.7)	315 (4.7)		
Native American or Alaska Native	4 (0.1)	4 (0.1)			Native American or Alaska Native	9 (0.1)	9 (0.1)		
Native Hawaiian or Other Pacific Islander	174 (4.5)	174 (4.5)			Native Hawaiian or Other Pacific Islander	39 (0.6)	39 (0.6)		
White	2,634 (67.4)	2,634 (67.4)			White	4,182 (62.9)	4,182 (62.9)		
Other	331 (8.5)	331 (8.5)			Other	813 (12.2)	813 (12.2)		
Unknown/Decline to State	0 (0.0)	0 (0.0)			Unknown/Decline to State	336 (5.1)	336 (5.1)		
Self-reported ethnicity (%)		. ,	1	< 0.001	Self-reported ethnicity (%)	()	. ,	1	< 0.001
Not Hispanic or Latino	3.672 (94.0)	3.672 (94.0)			Not Hispanic or Latino	5,732 (86,2)	5,732 (86.2)		
Hispanic or Latino	234 (6.0)	234 (6.0)			Hispanic or Latino	503 (7.6)	503 (7.6)		
Unknown/Decline to State	0 (0 0)	0 (0 0)			Unknown/Decline to State	411 (6.2)	411 (6 2)		
Birth year (mean (SD))	1025 52 (5.02)	1025 52 (5.02)	1	<0.001	Birth year (mean (SD))	1024 52 (10 11)	1024 50 (10.07)	0.927	0.004
Lifespan years (mean (SD))	80.05 (6.74)	80.07 (6.73)	0 945	0.001	Lifeenan years (mean(SD))	NA	NA	0.027	0.004
Autoimmuno disease status - True (%)	225 (6.0)	277 (0.73)	<0.040	0.002	Autoimmuno disease status = True (%)	415 (6.2)	575 (9 7)	<0.001	0.002
Autoimmune disease status – True (76)	233 (0.0)	311 (9.1)	<0.001	0.130	Autoimmune disease status – mue (76)	Cohort Study Design	575 (8.7)	<0.001	0.092
0	Short Study Design					Conort Study Design			
		Autoimmuno					Autoimmuno		
	Non-Autoimmune Controls	Autoimmune Disorder Patients	p value	SMD		Non-Autoimmune Controls	Autoimmune Disorder Patients	p value	SMD
N	Non-Autoimmune Controls	Autoimmune Disorder Patients 13.815	p value	SMD	N	Non-Autoimmune Controls	Autoimmune Disorder Patients 130.258	p value	SMD
N Sex (%)	Non-Autoimmune Controls 13,815	Autoimmune Disorder Patients 13,815	p value	SMD	N Sex = Male (%)	Non-Autoimmune Controls 130,258	Autoimmune Disorder Patients 130,258	p value	SMD
N Sex (%) Female	Non-Autoimmune Controls 13,815	Autoimmune Disorder Patients 13,815	p value	SMD <0.001	N Sex = Male (%) Female	Non-Autoimmune Controls 130,258 84 515 (64 9)	Autoimmune Disorder Patients 130,258	p value 1	SMD <0.001
N Sex (%) Female	Non-Autoimmune Controls 13,815 7,994 (57.9) 5.821 (42.1)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1)	p value 1	SMD <0.001	N Sex = Male (%) Female Male	Non-Autoimmune Controls 130,258 84,515 (64.9) 45 717 (35 1)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45 717 (35 1)	p value 1	SMD <0.001
N Sex (%) Female Male Linknoven/Decline to State	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0 0)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0 0)	p value 1	SMD <0.001	N Sex = Male (%) Female Male Linknoww/Decline to State	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0 0)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0)	p value 1	SMD <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%)	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0)	p value 1	SMD <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%)	Non-Autoimmune Controis 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0)	p value 1	SMD <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1 241 (9.0)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1 241 (9.0)	p value 1 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19 022 (14.6)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19 022 (14.6)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1 195 (8.7)	p value 1 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5 036 (3.9)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5.036 (3.9)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Unknown/Decline to State Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6)	p value 1 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alacka Native	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4)	p value 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native American or Alaska Native	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (7.9)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9)	p value 1 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native American or Alaska Native	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1.087 (0.8)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8 916 (64.5)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8 016 (5.5)	p value 1 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander Write	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72 (55.6)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 5559 (0.4) 1,087 (0.8) 72 757 (5.59)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3)	p value 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22 111 (17.0)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22 111 (17.0)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0)	p value 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawailan or Other Pacific Islander White Other Unknown/Decline to State	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9 696 (7.4)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self oncorted etholicity (%)	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,195 (8.7) 8,5 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,295 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0)	p value	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawailan or Other Pacific Islander White Other Unknown/Decline to State Self-exected etholicity (%)	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5.036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 5559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%)	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0)	p value 1 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%)	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 9,686 (7.4)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,339 (89.3) 42,339 (49.3)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,339 (89.3)	p value 1 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,59 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,688 (7.4) 101,442 (77.9)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 101,442 (77.9)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Black or African American Black or African American Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino Hispanic or Latino	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,339 (89.3) 1,476 (10.7)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,339 (89.3) 1,476 (10.7)	p value	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Black or African American Black or African American Native Hawaiian or Alaska Native Native Hawaiian or Alaska Native Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino Hispanic or Latino	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,688 (7.4) 101,442 (77.9) 17,816 (13.7)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 101,442 (77.9) 17,816 (13.7)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino Hispanic or Latino Unknown/Decline to State	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,339 (89.3) 1,476 (10.7) 0 (0.0)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 1,239 (89.3) 1,476 (10.7) 0 (0.0)	p value 1 1	SMD <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino Hispanic or Latino Unknown/Decline to State	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 101,442 (77.9) 17,816 (13.7) 11,000 (8.4)	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 101,442 (77.9) 17,816 (13.7) 11,000 (8.4)	p value 1 1	SMD <0.001 <0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawailan or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino Hispanic or Latino Hispanic or Latino Hispanic or Latino Hispanic or Latino Hispanic or Latino	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,339 (89.3) 1,476 (10.7) 0 (0.0) 1946.49 (13.43)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,339 (89.3) 1,476 (10.7) 0 (0.0)	p value 1 1 1 0.705	SMD <0.001 <0.001 <0.001	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawailan or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino Hispanic or Latino Hispanic or Latino Hispanic or Latino Hispanic or Latino Hispanic or Latino	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 101,442 (77.9) 17,816 (13.7) 11,008 (8.4) 1968.38 (21.83)	Autoimmune Disorder Patients 130,258 84,515 (64,9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 101,442 (77.9) 17,816 (13.7) 11,000 (8.4) 1968.38 (21.83)	p value 1 1 1 0.724	SMD <0.001 <0.001 0.001
N Sex (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Native American or Alaska Native Native Hawaiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino Hispanic or Latino Unknown/Decline to State Birth year (mean (SD)) Lifespan, years (mean (SD))	Non-Autoimmune Controls 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,339 (89.3) 1,476 (10.7) 0 (0.0) 1946.49 (13.43) 69.25 (13.21)	Autoimmune Disorder Patients 13,815 7,994 (57.9) 5,821 (42.1) 0 (0.0) 1,241 (9.0) 1,195 (8.7) 85 (0.6) 541 (3.9) 8,916 (64.5) 1,837 (13.3) 0 (0.0) 12,239 (89.3) 1,476 (10.7) 0 (0.0) 1946.55 (13.51) 69,10 (13.38)	p value 1 1 1 0.705 0.327	SMD <0.001 <0.001 <0.001 0.005 0.012	N Sex = Male (%) Female Male Unknown/Decline to State Self-reported race (%) Asian Black or African American Black or African American Black or African American Native Awawiian or Other Pacific Islander White Other Unknown/Decline to State Self-reported ethnicity (%) Not Hispanic or Latino Hispanic or Latino Unknown/Decline to State Birth year (mean (SD)) Lifespan, years (mean(SD))	Non-Autoimmune Controls 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 101,442 (77.9) 17,816 (13.7) 11,000 (8.4) 1968.38 (21.83) NA	Autoimmune Disorder Patients 130,258 84,515 (64.9) 45,717 (35.1) 26 (0.0) 19,022 (14.6) 5,036 (3.9) 559 (0.4) 1,087 (0.8) 72,757 (55.9) 22,111 (17.0) 9,686 (7.4) 101,442 (77.9) 17,816 (13.7) 11,000 (8.4) 1968.38 (21.83) NA	p value 1 1 1 0.724	SMD <0.001 <0.001 <0.001

776 777

778 Reports of 'NA' for lifespan indicate censored death information in the Stanford study groups. SMD =

779 Standardized Mean Difference, SD = Standard deviation